TY - JOUR
T1 - Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
AU - Bandello, Francesco
AU - de Benedetto, Umberto
AU - Knutsson, Karl Anders
AU - Parodi, Maurizio Battaglia
AU - Cascavilla, Maria Lucia
AU - Iacono, Pierluigi
PY - 2011
Y1 - 2011
N2 - Diabetic macular edema is the major cause of visual acuity impairment in diabetic patients. The exact etiopathogenesis is unknown and, currently, grid/focal retinal laser photocoagulation represents the recommended treatment. It has been demonstrated that vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of diabetic macular edema by mediating vascular permeability and accumulation of intracellular and extracellular fluid, and thereby represents an appealing candidate as a therapeutic target for the treatment of diabetic macular edema. The advent of intravitreal anti-VEGF drugs has opened up a new era for the management of diabetic macular edema. At present, three anti-VEGF substances are available for routine clinical use, ie, pegaptanib, ranibizumab, and bevacizumab. The aim of this review is to summarize the evidence supporting the use of ranibizumab in clinical practice. Most of the studies analyzed in this review are prospective, controlled clinical trials that have focused on documenting the therapeutic effect of ranibizumab and its safety, providing encouraging results.
AB - Diabetic macular edema is the major cause of visual acuity impairment in diabetic patients. The exact etiopathogenesis is unknown and, currently, grid/focal retinal laser photocoagulation represents the recommended treatment. It has been demonstrated that vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of diabetic macular edema by mediating vascular permeability and accumulation of intracellular and extracellular fluid, and thereby represents an appealing candidate as a therapeutic target for the treatment of diabetic macular edema. The advent of intravitreal anti-VEGF drugs has opened up a new era for the management of diabetic macular edema. At present, three anti-VEGF substances are available for routine clinical use, ie, pegaptanib, ranibizumab, and bevacizumab. The aim of this review is to summarize the evidence supporting the use of ranibizumab in clinical practice. Most of the studies analyzed in this review are prospective, controlled clinical trials that have focused on documenting the therapeutic effect of ranibizumab and its safety, providing encouraging results.
KW - Anti-VEGF
KW - Diabetic macular edema
KW - Ranibizumab
UR - http://www.scopus.com/inward/record.url?scp=81055144787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81055144787&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:81055144787
VL - 5
SP - 1303
EP - 1308
JO - Clinical Ophthalmology
JF - Clinical Ophthalmology
SN - 1177-5467
IS - 1
ER -